Y-Mabs Therapeutics Accounts Payable

The latest accounts payable for YMAB is $7.6M as of June 2025. That compares with $10M in the prior-year period — down 25.7% year over year. Investors often review this figure alongside Y-Mabs Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, YMAB's accounts payable moved from $10M to $7.6M — a 25.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Y-Mabs Therapeutics's operating scale or balance-sheet position.

A accounts payable figure of $7.6M for YMAB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting YMAB's accounts payable ($7.6M), review year-over-year change from $10M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Y-Mabs Therapeutics's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.